Comparative Pharmacology
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus CANTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus CANTIL.
ANISOTROPINE METHYLBROMIDE vs CANTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anisotropine methylbromide is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors (M1, M2, M3), thereby inhibiting parasympathetic nerve impulses. This leads to relaxation of smooth muscle in the gastrointestinal tract, decreased gastric acid secretion, and reduced motility.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Adult: 1-2 mg intramuscularly or subcutaneously every 4-6 hours as needed. Maximum: 8 mg/day.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
None Documented
None Documented
Clinical Note
moderateAnisotropine methylbromide + Fesoterodine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Fesoterodine."
Clinical Note
moderateAnisotropine methylbromide + Quinidine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Quinidine."
Clinical Note
moderateAnisotropine methylbromide + Topiramate
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Topiramate."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5-2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours).
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Primarily renal (approx. 70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%, mainly as metabolites.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Category C
Category C
Anticholinergic
Anticholinergic / Antispasmodic
Anisotropine methylbromide + Methadone
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Methadone."